Detectable safety gestalt of rheumatoid arthritis treatments from pivotal clinical drug trials
Abstract
Objective: To provide a meta-level comparison of standardized safety profiles ('gestalt') of currently licensed biologic and targeted synthetic disease-modifying anti-rheumatic drugs (bDMARDs and tsDMARDs) in rheumatoid arthritis (RA) from pivotal clinical trials.
Methods: We systematically searched EMBASE, Medline and the Cochrane Library for randomized controlled RA drug approval trials of bDMARDs and tsDMARDs. The Medical Dictionary for Regulatory Activities (MedDRA) hierarchy system was applied to account for the heterogeneous safety reporting across trials, and random-effects meta-analyses of adverse events (AE) were performed at lower MedDRA levels as well as for major system organ classes. Serious AEs (SAE) and AEs of special interest (AESI) were studied descriptively. Forest plots and radar charts were used for visualization, to generate distinct safety profiles, referred to as 'safety gestalt', for each compound.
Results: Sixty-four randomized, placebo-controlled drug approval trials were considered, of which 25 studied TNF-α inhibitors, 10 studied IL-6 receptor inhibitors, 5 studied rituximab, 7 studied abatacept and 18 studied Janus kinase inhibitors. Meta-level comparisons of the total number of AEs and SAEs showed comparable overall safety and tolerability, while a more granular insight into distinct organ classes and AESIs disentailed differences between compounds and drug classes.
Conclusion: Standardized safety reporting and profiling of bDMARDs and tsDMARDs…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Biportal endoscopic versus microscopic lumbar decompressive laminectomy in patients with spinal stenosis: A randomized controlled trial
- A whey protein-based multi-ingredient nutritional supplement stimulates gains in lean body mass and strength in healthy older men: A randomized controlled trial
- Supplement-based nutritional strategies to tackle frailty: A multifactorial, double-blind, randomized placebo-controlled trial
- A randomized, double-blind, placebo-controlled, proof-of-concept trial of creatine monohydrate as adjunctive treatment for bipolar depression
- Creatine supplementation (3 g/day) and bone health in older women: a 2-year, randomized, placebo-controlled trial
- A Multi-Ingredient Nutritional Supplement in Combination With Resistance Exercise and High-Intensity Interval Training Improves Cognitive Function and Increases N-3 Index in Healthy Older Men: A Randomized Controlled Trial
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.